Recent advances in drug treatments for dry eye disease
Authors:
- 17 October 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (18) , 2059-2079
Abstract
Dry eye disease (DED) is a common ocular condition with a significant impact on patients' quality of life. Conventional treatments include behavioral changes, tear substitutes and anti-inflammatory agents; however, recent advances in the understanding of DED pathogenesis have opened the way to the development of novel treatment strategies able to target several pathways involved in the onset and persistence of DED. Literature search was conducted on PubMed and Scopus around the term 'dry eye disease' and others involving its pathophysiology and therapeutic strategy. Primary focus were recent drugs approved by FDA or under investigation in phase 3 clinical trials. Google and ClinicalTrials.gov were used for obtaining information about the status of FDA approval and ongoing clinical trials. Due to its multifaced pathogenesis, DED management is often challenging, and patients' needs are frequently unmet. Recently, several novel treatments have been either FDA-approved or studied in late phase trials. These novel drugs target specific biological components of the ocular surface, reduce inflammation and ocular pain. Additionally, new drug delivery systems allow for increased bioavailability, improve effective dosing, and minimize ocular side effects. These advances in drug therapies show real promises for better management of DED patients.Keywords
This publication has 140 references indexed in Scilit:
- Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eyeClinical Ophthalmology, 2013
- Dry Eye as a Mucosal Autoimmune DiseaseInternational Reviews of Immunology, 2013
- A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patientsBritish Journal of Ophthalmology, 2012
- Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, NovasorbJournal of Drug Delivery, 2012
- Cell signalling by reactive lipid species: new concepts and molecular mechanismsBiochemical Journal, 2012
- TRPV1 Activation Is Required for Hypertonicity-Stimulated Inflammatory Cytokine Release in Human Corneal Epithelial CellsInvestigative Ophthalmology & Visual Science, 2011
- Novel Lipid Mediators and Resolution Mechanisms in Acute InflammationThe American Journal of Pathology, 2010
- Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cellsExperimental Eye Research, 2008
- Thymosin beta 4 suppression of corneal NFκB: A potential anti-inflammatory pathwayExperimental Eye Research, 2007
- A clinical study of the efficacy of topical corticosteroids on dry eyeJournal of Zhejiang University-SCIENCE B, 2006